Morgan Stanley’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-74,823
| Closed | -$1.41M | – | 6958 |
|
|
2019
Q3 | $1.41M | Sell |
74,823
-746,073
| -91% | -$8.53M | ﹤0.01% | 4074 |
|
|
2019
Q2 | $9.66M | Sell |
820,896
-12,290
| -1% | -$149K | ﹤0.01% | 2199 |
|
|
2019
Q1 | $11.4M | Sell |
833,186
-125,334
| -13% | -$1.62M | ﹤0.01% | 1916 |
|
|
2018
Q4 | $9.82M | Sell |
958,520
-171,516
| -15% | -$2.2M | ﹤0.01% | 2155 |
|
|
2018
Q3 | $18.8M | Sell |
1,130,036
-453,624
| -29% | -$8.2M | ﹤0.01% | 1744 |
|
|
2018
Q2 | $25M | Buy |
1,583,660
+387,037
| +32% | +$5.88M | 0.01% | 1439 |
|
|
2018
Q1 | $15.2M | Buy |
1,196,623
+39,786
| +3% | +$575K | ﹤0.01% | 1937 |
|
|
2017
Q4 | $13.2M | Buy |
1,156,837
+370,768
| +47% | +$4.14M | ﹤0.01% | 2107 |
|
|
2017
Q3 | $9.63M | Buy |
786,069
+51,490
| +7% | +$537K | ﹤0.01% | 2321 |
|
|
2017
Q2 | $8.41M | Buy |
734,579
+479,574
| +188% | +$8.87M | ﹤0.01% | 2339 |
|
|
2017
Q1 | $5.3M | Sell |
255,005
-65,290
| -20% | -$1.45M | ﹤0.01% | 2807 |
|
|
2016
Q4 | $6.66M | Buy |
320,295
+217,083
| +210% | +$5.64M | ﹤0.01% | 2693 |
|
|
2016
Q3 | $3.38M | Buy |
103,212
+92,393
| +854% | +$2.81M | ﹤0.01% | 3048 |
|
|
2016
Q2 | $270K | Buy |
10,819
+1,597
| +17% | +$43.2K | ﹤0.01% | 4787 |
|
|
2016
Q1 | $226K | Buy |
9,222
+2,758
| +43% | +$63.9K | ﹤0.01% | 4904 |
|
|
2015
Q4 | $214K | Sell |
6,464
-225,808
| -97% | -$7.64M | ﹤0.01% | 5053 |
|
|
2015
Q3 | $7.61M | Sell |
232,272
-26,652
| -10% | -$1.13M | ﹤0.01% | 2239 |
|
|
2015
Q2 | $13.7M | Buy |
258,924
+159,189
| +160% | +$5.79M | ﹤0.01% | 1814 |
|
|
2015
Q1 | $2.88M | Buy |
99,735
+91,959
| +1,183% | +$2.52M | ﹤0.01% | 3237 |
|
|
2014
Q4 | $226K | Buy |
7,776
+6,561
| +540% | +$118K | ﹤0.01% | 5180 |
|
|
2014
Q3 | $15K | Sell |
1,215
-78,104
| -98% | -$1.18M | ﹤0.01% | 6097 |
|
|
2014
Q2 | $1.59M | Buy |
+79,319
| New | +$1.12M | ﹤0.01% | 3673 |
|
Morgan Stanley's ALDR Position: Q4 2019 in Review
Morgan Stanley sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 74,823 shares — an estimated $1.41M sold.
Morgan Stanley first reported a position in ALDR in Q2 2014 and held it in 22 quarters. The position peaked at $25M in Q2 2018. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Morgan Stanley reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Morgan Stanley sold 74,823 Alder Biopharmaceuticals shares in Q4 2019, an estimated $1.41M.
- Morgan Stanley first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 22 quarters.
- Morgan Stanley's Alder Biopharmaceuticals position peaked at $25M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Morgan Stanley's 13F filing for Q4 2019, filed 14 Feb 2020.